By Editor , 1 October 2026 Fresenius Takes Full Ownership of mAbxience in Biosimilars Push Madrid – October 01, 2026 -- Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience from Insud Pharma, giving the German healthcare group full ownership of the Spanish biosimilars manufacturer.
